Purity
Greater than 95% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU/ug as determined by LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human TFRC at 2 μg/mL can bind Anti-TFRC recombinant antibody (CSB-RA023441MA1HU) , the EC50 is 3.305-8.220 ng/mL.
Alternative Names
Transferrin receptor protein 1; TR; TfR; TfR1; Trfr; T9; p90
Species
Homo sapiens (Human)
Expression Region
89-760aa
Target Protein Sequence
CKGVEPKTECERLAGTESPVREEPGEDFPAARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDENLALYVENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNMEGDCPSDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQRDAWGPGAAKSGVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLEGYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHVFWGSGSHTLPALLENLKLRKQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
Tag Info
N-terminal 10xHis-tagged
Form
Lyophilized powder
Note: We will preferentially ship the format that
we have in stock, however, if you have any special requirement for the format, please remark your
requirement when placing the order, we will prepare according to your demand.
Buffer
Lyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw
cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature
and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized
form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
Datasheet & COA
Please contact us to get it.
Description
The recombinant human transferrin receptor protein 1 (TFRC) was expressed in the mammalian cells. The human TFRC protein gene encoding fragment (89-760aa) fused with the 10xHis-tag gene at the N-terminus is cloned into a plasmid vector and then transfected into the mammalian cells. The transfected mammalian cells start expressing the recombinant TFRC protein, which is collected from the cell lysate. The purified recombinant TFRC protein undergoes rigorous quality control testing to ensure its identity, purity, activity, and endotoxin levels. Its purity is greater than 95% determined by SDS-PAGE and endotoxin content is less than 1.0 EU/ug measured by the LAL method. In a functional ELISA, immobilized human TFRC at 2 μg/mL can bind the anti-TFRC recombinant antibody (CSB-RA023441MA1HU), with the EC50 of 3.305-8.220 ng/mL.
TFRC, as an essential mediator of normal iron metabolism in the human body, primarily assists in the transport of transferrin inside and outside the cells and across the blood-brain barrier, maintaining cellular iron balance. TFRC is lowly expressed in all normal nuclear cells, but exhibits higher expression levels in immature proliferating cells and significantly increased expression in tumor cells. The upregulation of TFRC expression in malignant cells and its central role in cancer pathology make TFRC an attractive target for antibody-mediated cancer therapy. TFRC has also been an important target receptor for drug transport across the blood-brain barrier. By targeting TFRC on the surface of the blood-brain barrier, specific drugs can be delivered to the brain parenchyma, potentially improving the treatment of diseases such as Alzheimer's, Parkinson's, and acute stroke. Developing active mammalian TFRC proteins is of great significance in further studying TFRC's function and developing tumor drugs.
